Genomic imprinting is a mechanism of differentially epigenetic modification that restricts monoallelic expression to either the maternally or paternally inherited copy of the gene during gametogenesis. Imprinted methylation undergoes a process of erasure, acquisition, and maintenance during gametogenesis and early embryogenesis. Disruptions in any of these steps may lead to imprinting disorders, resulting in the aberrant development of embryogenesis, placentation and postnatal growth. Recent studies have shown that maternal-effect proteins are important for the regulation of imprinted gene during the development of preimplantation embryos. In order to obtain a better understanding for the mechanism of maternal-effect proteins in the maintenance of genomic imprints, the recent study progress of maternal-effect proteins, such as DPPA3, ZFP57, TRIM28 and DNMT1, are summarized, and the regulation mechanism of these maternal-effect proteins for genomic imprints are discussed.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3724/SP.J.1005.2014.0959 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The effect of inhaled nitric oxide treatment on biomarkers of oxidative/nitrosative damage to proteins and DNA/RNA.
Free Radic Biol Med
January 2025
Neonatal Research Group, Health Research Institute Hospital La Fe (IISLAFE), Avda Fernando Abril Martorell 106, 46026, Valencia, Spain; Spanish Network in Maternal, Neonatal, Child and Developmental Health Research (RICORS SAMID) (RD24/0013/0014), Instituto de Salud Carlos III, Madrid, Spain; Division of Neonatology, University & Polytechnic Hospital La Fe, Avda Fernando Abril Martorell 106, 46026, Valencia, Spain. Electronic address:
Inhaled nitric oxide (iNO) is a selective pulmonary vasodilator that is used as a treatment for persistent pulmonary hypertension in neonates (PPHN) with hypoxic respiratory failure. The generation of reactive oxygen and nitrogen species might induce oxidative/nitrosative damage to multiple organs. There is an increasing scientific and clinical interest in the determination of specific biomarkers to measure the degree of oxidative/nitrosative stress in non-invasively collected biofluids.
View Article and Find Full Text PDFAntagonisation of Prokineticin Receptor-2 Attenuates Preeclampsia Symptoms.
J Cell Mol Med
January 2025
Interdisciplinary Research Institute of Grenoble, IRIG-Biosanté, University Grenoble Alpes, INSERM, CEA, UMR 1292, Grenoble, France.
Preeclampsia (PE) is the most threatening pathology of human pregnancy. Placenta from PE patients releases harmful factors that contribute to the exacerbation of the disease. Among these factors is the prokineticin1 (PROK1) and its receptor, PROKR2 that we identified as a mediators of PE.
View Article and Find Full Text PDFPreterm preeclampsia screening and prevention: a comprehensive approach to implementation in a real-world setting.
BMC Pregnancy Childbirth
January 2025
Genetic Program, North York General Hospital, Toronto, ON, Canada.
Background: Preeclampsia significantly impacts maternal and perinatal health. Early screening using advanced models and primary prevention with low-dose acetylsalicylic acid for high-risk populations is crucial to reduce the disease's incidence. This study assesses the feasibility of implementing preterm preeclampsia screening and prevention by leveraging information from our current aneuploidy screening program in a real-world setting with geographic separation clinical site and laboratory analysis site.
View Article and Find Full Text PDFCombined anti-leukemic effect of gilteritinib and GSK-J4 in FLT3-ITD acute myeloid leukemia.
Transl Oncol
January 2025
The First Clinical Medical College of Lanzhou University, Lanzhou 730000, China; Department of Hematology, The First Hospital of Lanzhou University, Lanzhou 730000, China. Electronic address:
Gilteritinib treats acute myeloid leukemia (AML) with the FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation. Dysregulation of histone modification affects the genesis and progression of AML. Strategies targeting key histone regulators have not been applied to the treatment of AML.
View Article and Find Full Text PDFIntroduction: Giant omphalocele poses a conflict between eviscerated content and abdominal capacity, with associated risks such as compartment syndrome or cardiovascular compromise.
Clinical Case: We present the case of a prenatally diagnosed hepato-omphalocele, without associated abnormalities. At week 37, botulinum toxin was injected in the right hemiabdomen under fetal and maternal sedation.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!